Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Xiaoyang Li, Jian Zhang, Yuanchao Xie, Yuqi Jiang, Zhang Yingjie and Wenfang Xu
Affiliation: Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, China.
Keywords: Combined therapy, hematologic malignancies, histone deacetylase inhibitors, monotherapy, panobinostat, solid
Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones
by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is
closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the
last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the
pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both
preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical
studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
Rights & PermissionsPrintExport